Sentences with phrase «vaccine regimen»

Make sure that any young dogs and cats have completed their puppy and kitten vaccine regimen and that your adults are up - to - date.

Research Trials The HVTN also plans to test other HIV vaccine regimens in Southern Africa in a parallel research track using multiple vaccine candidates.

At the first plenary session of AIDS Vaccine 2011, which opened this morning in Bangkok, Thailand, researchers presented the results of a two - year - long effort to try to identify an immunological explanation for the modest 31 % efficacy afforded by the prime - boost vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infection.

• RV217 (ECHO): HIV - 1 Prevalence, Incidence, Cohort Retention, and Host Genetics and Viral Diversity in High Risk Cohorts in East Africa • Infectious Disease Surveillance (HIV, TB and Malaria) and Cohort Development Among Urban and Rural Communities • Karolinska Institute vaccine study in Tanzania testing a prime - boost HIV vaccine regimen using unadjuvanted DNA vaccines followed by a Modified Vaccinia Ankara (MVA), which was developed by MHRP and NIAID.

A small Phase I trial to evaluate the RV144 vaccine regimen in 100 volunteers in South Africa began in June 2013.

The experimental vaccine regimen tested in the RV144 trial was found to be 31.2 percent effective at preventing HIV infection 3.5 years after vaccination, although it appears to have been 60 percent effective one year after vaccination.

The U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR) initiated a Phase 2 clinical trial to evaluate the safety and immunogenicity of a prime - boost Ebola vaccine regimen in both healthy and HIV - infected volunteers.

We are testing two novel preventive vaccine regimens, and for the first time we're testing the idea of using a broadly neutralizing antibody administered passively.

A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants.

Recently, monkey studies testing vaccine regimens different from those in RV144 have supported the notion that enhancing protective antibody activity may increase vaccine efficacy.

Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.

If the WHO grants an emergency use listing, this will accelerate the availability of Janssen's investigational vaccine regimen to the international community in the event another Ebola crisis occurs.»

«We seek to make TB vaccine regimens for infants and adolescents available and licensed in the next seven to nine years,» according to Yasir Skeiky, chief scientific officer of Aeras.

Meanwhile, phase 1 trials are to begin early next year for a two - vaccine regimen involving an adenovirus - based vaccine developed by US pharmaceutical company Johnson & Johnson and the NIAID, and a vaccine that is made from vaccinia (a virus similar to the one that causes cowpox) developed by Bavarian Nordic in Denmark.

A new study led by scientists at Beth Israel Deaconess Medical Center (BIDMC) shows that an HIV - 1 vaccine regimen, involving a viral vector boosted with a purified envelope protein, provided complete protection in half of the vaccinated non-human primates (NHPs) against a series of six repeated challenges with simian immunodeficiency virus (SIV), a virus similar to HIV that infects NHPs.

An HIV - 1 version of the promising vaccine regimen is now being evaluated in an ongoing Phase 1 / 2a international clinical study.

«Novel HIV vaccine regimen provides robust protection in non-human primates.»

Though these particular vaccine regimens are not intended for the clinic, the results suggest that effective vaccines for MERS could be developed from the Spike protein, says study coauthor Barney Graham, a vaccinologist at the National Institute of Allergy and Infectious Diseases in Bethesda, Md..

He is the current protocol chair of HVTN 505, a phase 2b test - of - concept efficacy study of the preventive HIV vaccine regimen developed by NIAID's Vaccine Research Center.

This current vaccine trial, called HVTN 702, is testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults.

Follow - up clinical studies using modified vaccine regimens and extra boosts are set to begin in Southern Africa in 2015.

The HIV Vaccine Trial Network (HVTN) plans to conduct clinical trials in heterosexual adults that will evaluate a prime - boost vaccine regimen similar to that used in RV144 adjusted to target the most common subtype of HIV in the region (subtype C).

The new Ad26 / MVA and Ad35 / Ad26 vector - based vaccine regimens resulted in over 80 % reduction in the per - exposure probability of acquisition of infection against repetitive challenges of SIV, a virus similar to HIV that infects monkeys.

At the International AIDS Society conference in Paris, scientists announced that in an early - stage clinical trial, a new HIV vaccine regimen generated antibody responses in 100 percent of volunteers in most arms of the study.

It would not be included in most dogs» annual core vaccine regimen; but, for high - risk animals it may be warranted.

Dogs that go to doggie day care, dog parks and get boarded and groomed also benefit from customized vaccine regimens, temperament testing and an awareness that they're more likely to contract infections than dogs that have limited dog - to - dog interaction.

Guided by findings from human and monkey studies, researchers are working to improve upon the efficacy of the RV144 vaccine regimen.

The Walter Reed Army Institute of Research (WRAIR) today announced the initiation of a Phase 2 clinical trial to evaluate the safety and immunogenicity of a prime - boost Ebola vaccine regimen in... Read More

This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program - led RV144 clinical trial in Thailand — the first study to demonstrate that a vaccine can protect people from HIV infection.

ALVAC ® — HIV and AIDSVAX ® B / E Prime — Boost HIV — 1 Preventive Vaccine Regimen: Final Results of the Phase III Community — based Trial in Thailand

Study will evaluate a prime - boost Ebola vaccine regimen in both healthy and HIV - infected volunteers

Collaborators are planning clinical testing of this HIV vaccine regimen in healthy adults at research sites in the U.S., East Africa, South Africa, and Thailand.

The vaccine regimens were described in a previous publication.

Based on these pre-clinical data, the HIV - 1 version of this vaccine regimen is now being evaluated in an ongoing Phase 1 / 2a international clinical study sponsored by Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

In the HVTN 100 study, the design and schedule of the RV144 vaccine regimen have been altered to try to increase the magnitude and duration of vaccine - elicited immune responses.

The vaccine regimen tested in the study has two components.

The results of the HVTN 100 trial, expected in two years, will help determine whether or not this vaccine regimen will be tested for efficacy in a large future study in South Africa.

Conclusion: The ALVAC - HIV and AIDSVAX B / E prime - boost HIV vaccine regimen may reduce the risk of HIV infection in a community - based population in Thailand with largely heterosexual risk and did not affect post-infection viral load or CD4 count.

It is working to improve the efficacy of that vaccine regimen and also accelerate the development of novel vaccine combinations.

In September, the team added to the vaccine regimen a drug called Keytruda that supports the immune system's attack on tumors.

The object of this partnership would be to take the RV144 vaccine regimen and create a more effective vaccine.

Results from an initial study to ensure that the RV144 vaccine regimen is safe and well - tolerated in South African volunteers were reported at the 2014 HIV Research for Prevention (R4P) conference.

Another clinical study, RV306, began in September 2013 using the RV144 vaccine regimen to compare additional vaccine boosts and gather more immunogenicity data in 360 new volunteers.

IgG Antibody Responses to Recombinant gp120 proteins, gp70V1 / V2 Scaffolds and a CyclicV2 Peptide in Thai Phase I / II Vaccine Trials using Different Vaccine Regimens.

The development track will begin with a Phase I trial to test the vaccine regimen's safety and immunogenicity and depending on those study results, a larger efficacy study will follow.

Improving the Vaccine Regimen Researchers have discovered important clues about the immune responses that may have played a role in protecting some volunteers in RV144.

This trial, HVTN 097, aimed to ensure that the vaccine regimen tested in Thailand, targeting subtypes B and E, is safe and well - tolerated in this population.

The National Institutes of Health and partners have launched a large clinical trial to assess whether an experimental HIV vaccine regimen is safe and able to prevent HIV infection.

The vaccine regimen tested in the study combined a priming vaccine developed by Sanofi Pasteur (ALVAC ® HIV vCP1521) and GSID's boosting vaccine (AIDSVAX ® B / E).

The top - line results of the placebo controlled study in 16,000 Thai volunteers were released today, and according to the sponsors of the trial, demonstrated that the vaccine regimen reduced HIV infection in a community - based population by 31.2 % compared with placebo.